ViroPharma Inc. (Nasdaq:VPHM) announced the modernization of labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application (sNDA). The company also provided updates on ViroPharma's ongoing citizen petition and litigation with the FDA regarding Vancocin.

Read the full article at: http://stockhottips.com/?p=19881

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

*******************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. StockHotTips.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://stockhottips.com/disclaimer)is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.